Skip to main content

Table 2 Adverse events experienced by ≥2 Patients (n = 120)

From: Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study

Adverse Event

Any Grade

Grade 3–4

No.

%

No.

%

Stomatitis

28

23.3

11

9.2

Rash

10

8.3

1

0.8

Increased ALT or AST

6

5.0

3

2.5

Cough

6

5.0

2

1.7

Anorexia

5

4.2

2

1.7

Asthenia

5

4.2

0

0.0

Dyspnea

4

3.3

0

0.0

Pneumonitis

3

2.5

0

0.0

Nausea

3

2.5

1

0.8

Hyperglycemia

2

1.7

0

0.0

Neutropenia

2

1.7

1

0.8

Diarrhea

2

1.7

0

0.0

Fever

2

1.7

0

0.0

Maxillary necrosis

2

1.7

0

0.0

Venous thrombosis

2

1.7

0

0.0

  1. NOTE. Adverse events listed regardless of relationship to study drug
  2. Abbreviations: ALT alanine aminotransferase, AST aspartate aminotransferase
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us